ViferaXS, a clinical-stage biotechnology company based in Tübingen, Germany, has announced the closing of a Series A financing round worth up to €12 million, including grant funding. The investment was led by SPRIND, the German Federal Agency for Breakthrough Innovation, and Huma, with additional participation from private investors. The new capital will support a Phase II clinical trial in chronic lymphocytic leukemia and other pipeline programs.
Funding Round Details
The financing round was announced on September 23, 2026, and combines private investment with non-dilutive grant funding. SPRIND and Huma served as the lead investors, while a group of private investors also joined the syndicate. This structure brings the total available capital to as much as €12 million for ViferaXS.
Clinical Development Plans
The proceeds will primarily fund a randomized Phase II trial of CLLTAXS01 in patients with chronic lymphocytic leukemia, also known as CLL. In parallel, ViferaXS expects to share Phase I data from its programs in acute myeloid leukemia and fibrolamellar carcinoma. The company also plans to expand its team and advance preclinical research in additional oncology indications.
Executive Perspectives
Sezai Taskin, Chief Executive Officer of ViferaXS, said the early clinical data for CLLTAXS01 encouraged the company to move into a randomized Phase II study. He added that upcoming Phase I readouts in acute myeloid leukemia and fibrolamellar carcinoma will help demonstrate how peptide-based cancer immunotherapy may transform patient care. Patrick Rose, Innovation Manager at SPRIND, described ViferaXS as a clinically grounded, high-ambition project that fits the agency's mission to accelerate breakthrough innovation.
Strategic and Technological Support
Dan Vahdat, Founder and CEO of Huma, said the company is building an operating system for clinical trials that brings data, intelligence, and execution into one platform. Huma is backing ViferaXS through both investment and technology to help accelerate new cancer therapies. The collaboration is intended to streamline clinical development and support the company's broader mission in oncology.
About the ViferaXS Platform
ViferaXS is a spin-out of the Eberhard Karls University Tübingen and develops cancer immunotherapies for hematologic malignancies and solid tumors. Its proprietary T Cell Activator technology is designed to activate cytotoxic T cells against naturally presented tumor antigens. The clinical pipeline spans three oncology indications: acute myeloid leukemia, chronic lymphocytic leukemia, and fibrolamellar carcinoma.
Investor Background
SPRIND is Germany's federal agency for breakthrough innovation, established in 2019 and owned by the Federal Republic of Germany. It funds high-ambition projects that often lack sufficient private-sector support and works to retain innovation value in Germany and Europe. Huma is a technology company building an operating system for artificial intelligence in regulated industries, with roots in healthcare and life sciences.
With this Series A financing, ViferaXS gains both the financial resources and strategic support needed to advance its clinical pipeline at a pivotal stage. The company's focus on peptide-based immunotherapy addresses an important need in hematologic malignancies and rare solid tumors. As Phase II and Phase I data emerge, ViferaXS may offer new evidence for the potential of T cell activation in cancer care.